This notion has been further supported by evidence from more relevant bleomycin (BLM) induced lung fibrosis model, in which treatment with anti‐IL‐22 neutralizing antibody exacerbated airway inflammation and enhanced expressions of a number of fibrotic biomarkers.14 The gene discussed is IL22; the disease is pulmonary fibrosis.